Accueil・Liste d'Actions・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Fermé

15.65 2.89

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

15.14

Max

15.63

Chiffres clés
By Trading Economics
Revenu	-1.4M -14M
BPA	-0.15
Employés	37
EBITDA	312K -12M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+108.31% upside

Dividendes
By Acuity
Prochains Résultats	6 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-199M 1.1B
Ouverture précédente	12.76
Clôture précédente	15.65

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

6 juil. 2026, 23:56 UTC

Correlated Moves

Costco Wholesale Corp's shares are lower in after-market hours, reflecting a slight decline since Monday's close amid broader market trends.

6 juil. 2026, 23:56 UTC

Biogen Inc. shares are higher in after-market trading, reflecting a slight upward movement since Monday's close and settling near the upper end of their one-month range.

6 juil. 2026, 23:56 UTC

ETF Constituents

SPDR S&P Regional Banking ETF shows gains in after-market trading, driven by contributions from Citizens Financial Group and East West Bancorp.

6 juil. 2026, 23:56 UTC

Correlated Moves

ETF Constituents

Vanguard Information Technology ETF shows little change in after-market trading, with top contributors AMD, Microsoft, and NVIDIA posting slight negative returns.

6 juil. 2026, 23:52 UTC

Correlated Moves

Social Media

Lam Research shares decline in after-market trading amid broader market weakness and recent insider selling of $11.70 million by Timothy Archer.

6 juil. 2026, 23:52 UTC

Mixed trading in European equity indices as Germany's DAX rises on strong factory orders, while FTSE 100 and CAC 40 dip amid disappointing retail sales and cautious ECB outlook.

6 juil. 2026, 23:52 UTC

Asia equity markets rise on tech sector optimism, while U.S. mega-cap stocks gain amid strong dollar and mixed European indices ahead of key economic data releases.

6 juil. 2026, 23:52 UTC

Global equity markets show mixed performance as U.S. and Asian indices rise while European stocks decline, amid varied economic data signaling resilience in services and manufacturing sectors.

6 juil. 2026, 23:52 UTC

U.S. equity markets remain flat post-holiday, with mega-cap tech stocks rising amid expectations of a Federal Reserve interest rate pause following a weak jobs report.

6 juil. 2026, 23:52 UTC

Japan's Household Spending Declines 0.4% YoY in May, Beating Expectations and Signaling Potential Recovery Amid Ongoing Inflation Pressures

6 juil. 2026, 23:52 UTC

Japan's Household Spending Surges 3.7% MoM in May, Exceeding Expectations and Indicating Consumer Confidence Recovery

6 juil. 2026, 23:52 UTC

China's June 2026 Inflation Rate Release Expected at 1.1% Amid Cautious Market Sentiment and Global Economic Influences

6 juil. 2026, 23:52 UTC

China's Producer Prices Expected to Rise 4.2% YoY Amid Inflationary Pressures and Strong Manufacturing Sentiment Ahead of July 9 Release

6 juil. 2026, 23:52 UTC

Initial Jobless Claims Expected at 220,000 Amid Rising Concerns Over Labor Demand and Economic Outlook

6 juil. 2026, 23:52 UTC

China's Inflation Rate Expected to Decrease Slightly by 0.002% in June Amid Global Economic Caution

6 juil. 2026, 23:52 UTC

Canada's Ivey PMI forecasted to rise to 59.1 amid recent economic contraction signals and geopolitical uncertainties impacting business confidence.

6 juil. 2026, 23:51 UTC

ETF Constituents

Macro News

Geopolitical tensions are driving modest gains for the Energy Select Sector SPDR Fund after-market hours, supported by positive contributions from Exxon Mobil and Chevron.

6 juil. 2026, 23:51 UTC

Kraft Heinz Co. shares are lower in after-market trading, reflecting routine movement amid a slight decline in U.S. services PMI and weaker job additions.

6 juil. 2026, 23:51 UTC

Fiserv Inc shares are higher in after-market trading, moving near the upper end of their one-month trading range. No specific news was identified for this increase.

6 juil. 2026, 23:51 UTC

Correlated Moves

Applied Materials shares are lower in after-market trading, continuing a trend of four consecutive sessions of losses amid broader market weakness and macroeconomic concerns.

6 juil. 2026, 23:46 UTC

Correlated Moves

ETF Constituents

Vanguard FTSE Europe ETF traded near unchanged levels in after-market hours, influenced by slight declines in top holdings SAP and BP.

6 juil. 2026, 23:46 UTC

Shares of Workday Inc. are lower in after-market trading. The U.S. services PMI fell to 54.0, indicating a slight slowdown in sector expansion.

6 juil. 2026, 23:46 UTC

Correlated Moves

U.S. services PMI fell to 54.0 in June, matching expectations. The Dow Jones Index is trading roughly flat amid cautious sentiment on Fed interest rates.

6 juil. 2026, 23:46 UTC

Intuitive Surgical shares are higher in after-market trading, continuing an upward trend from the previous three sessions. No specific news was identified for the move.

6 juil. 2026, 23:46 UTC

United States Oil Fund LP is trading higher in after-market hours, reflecting a recovery from earlier fluctuations amid mixed global equity performance.

6 juil. 2026, 23:41 UTC

Verisk Analytics Inc shares declined during after-market hours, despite a broader market context showing continued expansion in the services sector. No specific news was identified.

6 juil. 2026, 23:41 UTC

Correlated Moves

Vanguard Total International Bond ETF rises in after-market trading, reflecting positive bond market sentiment and stability near its one-month trading range.

6 juil. 2026, 23:41 UTC

Cognizant Technology Solutions shares are higher in after-market trading, amid broader market assessment of U.S. Services PMI and last week's nonfarm payrolls report.

6 juil. 2026, 23:41 UTC

Correlated Moves

Social Media

News

Micron Technology shares are lower in after-market trading, reflecting broader market pressures and concerns over a potential memory oversupply by 2028.

6 juil. 2026, 23:41 UTC

ETF Constituents

iShares MSCI Brazil ETF gains in after-market trading, supported by positive sentiment in global equity markets and contributions from PBR.

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

108.31% hausse

Prévisions sur 12 Mois

Moyen 31.6 USD 108.31%

Haut 40 USD

Bas 27 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

5 ratings

Achat

Maintien

Vente

Basé sur 5 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.